iDEAL Semiconductor has announced its first family of 200-V MOSFETs based on high-performance SuperQ technology. The SuperQ architecture increases silicon utilization from 50% to 95%, increasing ...

Tresiba (insulin degludec) has potential interactions with alcohol, other medications, and some supplements. These interactions could affect how well the drug works or cause harmful effects. Tresiba ...

The Chrysler 200 entered the market in 2011 with hopes of capturing attention in the competitive world of midsize sedans. It featured a sleek design and aimed to offer a mix of style, performance, and ...

Tresiba (insulin degludec) may not be safe to use while pregnant or breastfeeding. Factors including the form you take or the condition being treated may determine whether you should use the drug ...

The Olympic gold medalist shares his technique for the sprint that requires a special blend of power, speed, endurance and strategic decision-making. After winning the 100-meter dash, Lyles looks to ...

Meet Jasper Schmich Kinney, your go-to tech guru and gaming aficionado. Jasper is a video game music composer, having collaborated with industry legends like Yasunori Nishiki (composer of the Octopath ...

I write about Tech for Forbes Finds. The speakers built into your TV aren’t great, but thankfully you don’t have to spend much to get a radically better home theater audio experience. The best ...

In March 2013, Novo Nordisk launched Tresiba (insulin degludec), its new once-daily basal insulin for type 1 and type 2 diabetes, in the UK and Denmark. Tresiba will be priced roughly 70% higher than ...

The Verizon 200 at the Brickyard will mark the 3rd time the NASCAR Cup Series has raced on the road course. After using the oval layout since 1994, in 2021 the Cup Series switched to the 2.4 mile road ...

Tresiba (insulin degludec) is a brand-name drug that’s prescribed for diabetes. The medication is available as a liquid vial and a prefilled injection pen. The cost of Tresiba with and without ...

Novo Nordisk (NVO) said new data from a phase 3a trial showed that more people with type 2 diabetes achieved blood sugar target with once-weekly insulin icodec compared with its own once-daily therapy ...